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Background: There is conﬂicting evidence about the importance of airway mucins (MUC5AC and MUC5B) in determining physical properties
of sputum in cystic ﬁbrosis (CF). We studied the effects of endogenous degradation of mucins on CF sputum elasticity and apparent mucin
concentrations.
Methods: Elastic shear moduli (G′) and mucin concentrations in sputum of 12 CF patients were measured before and after incubation at 37 °C for
60 min.
Results: G′ fell from a median of 5.98 to 4.70 Pa (p = 0.01). There were signiﬁcant falls in MUC5AC (8.2 to 5.2 μg/ml, p = 0.02) and MUC5B
(17.3 to 12.5 μg/ml, p = 0.02) over the same period, and associated decrease in molecular weight and size.
Conclusions: Sputum is not inert and degradation reduces apparent mucin concentrations and sputum elasticity. Even if care is taken to process
samples rapidly, sputum may therefore differ from secretions retained in airways. Previous studies may have underestimated the role of mucins in
CF sputum.
© 2013 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic ﬁbrosis; Mucin; Proteolysis; Lung inﬂammation1. Introduction
Cystic fibrosis (CF) is characterized by chronic airway infection
and inflammation, and clinically by accumulation of airway
secretions [1]. Clearance of these secretions is a major objective of
CF care, typically involving daily physiotherapy [2]. The physical
properties of sputum, which determines the ease or otherwise of
airway clearance strategies, reflect a complex interaction between
different macromolecular components, ions and hydration. The
influence of these different components however is incompletely
understood.⁎ Corresponding author at: Manchester Adult Cystic Fibrosis Centre, University
Hospital South Manchester, Manchester M23 9LT, UK.
E-mail address: alexander.horsley@manchester.ac.uk (A. Horsley).
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http://dx.doi.org/10.1016/j.jcf.2013.11.002Sputum is a complex mix of airway mucins, DNA, proteins,
and bacterial and host inflammatory cells [3,4]. This is quite
distinct from normal airway mucus which consists predominantly
of water, ions, proteins and the secreted airway mucins MUC5AC
and MUC5B [5]. In the healthy airway, these polydisperse large
molecular weight glycoproteins perform an important role in
airway defence and hydration [5]. MUC5AC is secreted mainly
from goblet cells in the surface respiratory epithelium andMUC5B
predominantly from submucosal glands [6].
Mucin production is upregulated in response to a range of
airway insults [7]. In CF, the airway is exposed to a wide range of
such stimuli, including endobronchial infection with Pseudomonas
aeruginosa [8] and Staphylococcus aureus [9], that have been
shown to activate NF-κB and upregulate mucin gene transcription
[7]. Both goblet cell hyperplasia [6] and increased submucosalby Elsevier B.V. All rights reserved.
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suggesting either a chronic increase in production of mucins or a
failure to release mucins from goblet cells [11].
Despite the central role of airway secretions in the patho-
physiology and symptomatology of CF, there is disagreement
about the importance of mucins in determining the physical
properties of CF sputum. Reliably identifying different mucin
subtypes is a challenging and complex process involving solu-
bilization and separation of mucins, and recognition by specific
antibodies [12]. Early analyses indicated that, weight for weight,
there was around twice as much mucin as DNA in CF sputum
[13]. More recent attempts at quantification of mucin levels in
CF however have shown intriguing results, with levels of both
MUC5AC and MUC5B reportedly substantially lower in CF
sputum than in secretions from healthy airways [11]. Although
subsequently shown to increase during a pulmonary exacerba-
tion, mucin levels remained the same or less than those found in
healthy secretions [14]. This raises questions about the importance
of mucins in CF sputum. Could low mucin levels be a con-
sequence of bacterial infection (e.g. due to mucin degradation)
or an underlying cause (e.g. might altered mucin profiles be
responsible for the characteristic infections seen in CF)? Airway
blockage seen in very young children with no evidence of infection
[15] suggests that in the absence of large amounts of bacterial and
inflammatory cell DNA mucins alone may be responsible for
airway obstruction. Greater understanding of the role of mucins in
airway pathophysiology is important therefore at all stages of this
complex disease, and has implications for future research and
treatments.
We hypothesized that mucins were subject to significant
degradation within sputum from CF patients, and that this could
explain the previous conflicting evidence on the role of mucins in
CF sputum.We assessed mucin degradation in vitro by examining
the effect of incubation at 37 °C on sputum elasticity and airway
mucin concentrations. The aims of this study were thus to:
1) assess the effect of endogenous degradation on elasticity of
CF sputum; 2) assess the effect of depolymerization of DNA and
mucins on elasticity; 3) quantify the levels of airway mucins
MUC5AC and MUC5B in CF sputum; and 4) assess the effects
of degradation of MUC5AC and MUC5B on apparent mucin
concentrations.2. Methods
2.1. Subjects
This was an observational study of adults with CF undergoing
treatment for a pulmonary exacerbation. Exacerbation was defined
clinically and all patients were assessed within 24 h of com-
mencement of therapy.
Spirometry was performed according to ATS/ERS guidelines.
Baseline forced expiratory volume in 1 s (FEV1) was taken as the
highest in the preceding 6 months. Body mass index (BMI) was
calculated at the time of sputum collection. 24 h sputum load was
given as the total weight of sputum expectorated over the
preceding 24 h.The study was approved by the North West Research Ethics
Committee (study reference 10/H1014/71) and all patients
provided written informed consent.
2.2. Sputum processing
Sputum samples were collected by spontaneous expectora-
tion over no more than 5 min and transported on ice for rapid
processing (collection to storage within 30 min). Whole sputum
was transferred to a sterile Petri dish and sputum samples separated
out into pre-weighed tubes. Samples were frozen at −80 °C for
storage prior to analysis.
2.3. Elasticity
Following thawing at 37 °C for 5 min, 100 μl of sputum was
aliquoted using a positive displacement pipette (Brand GMBH,
Wertheim, Germany). Rheology was assessed using a controlled
stress rheometer (Bohlin HR Gemini, Malvern Instruments,
Worcestershire, UK) and 20 mm/2° cone maintained at 37 °C by
the Peltier plate. Sample drying was prevented by application of a
thin layer of mineral oil (Sigma-Aldrich, Dorset, UK) around the
edge of the cone. Storage (elastic) shear moduli (G′), reflecting
solid-like properties or overall degree of cross-linking in the
sample, and loss (viscous) shear moduli (G″) were calculated from
the measured response of the samples to an oscillating angular
displacement. Frequency sweeps were performed between
0.5–10 Hz with a stress of 1 Pa (within the linear viscoelastic
range). Data are quoted as the mean of 3 repeats at 1 Hz.
2.4. Degradation of mucins and DNA
In order to assess the effect of endogenous degradative
processes, serial rheological and mucin analyses were made at
intervals after commencing incubation at 37 °C. Sputum was
gently mixed prior to removal of aliquots. All samples were
assayed at time 0 and 60 min.
Two samples with minimal rheological change on simple
incubation were subjected to additional analyses to assess the
relative contribution of DNA and mucins to overall sputum
elasticity. Each of three 200 μl aliquots was treated with 10 μl of
either 0.9% saline, recombinant human DNase (final concentra-
tion 2.5 μg/ml) or dithiothreitol (DTT) (final concentration of
10 mM). Half was analyzed immediately and the remainder was
incubated at 37 °C for 60 min before elasticity measurements
were repeated.
2.5. Quantification of MUC5AC and MUC5B
Mucins were separated by agarose gel electrophoresis and
Western blotting, as previously described [12]. Mucins were
reduced prior to separation by addition of 10 μl 100 mM DTT
and heating to 100 °C for 15 min, or separated whole and
reduced prior to transfer by soaking the gel in 200 ml 0.6 M
NaCl/60 mM sodium citrate buffer (SSC) containing 10 mM
DTT for 30 min. The polyclonal antibodies MAN5AC-I and
MAN5BIII were used to identify separated mucins, MUC5AC
Fig. 1. Change in elastic modulus (G′) of CF sputum samples incubated at 37 °C
for 60 min. Each pair of points represents the same sputum sample assayed at 2
time points, horizontal bars represent group medians. 3 patients who had received
nebulized DNase within 12 h of sampling are offset and highlighted in gray with
dotted joining bars. There was no difference in baseline elastic modulus between
these three and the remaining 9 patients, nor in G′ change with incubation.
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from a standard curve of purified mucins, run on the same gel
[17,18].
2.6. Mucin purification & molecular weight determination
Selected samples were purified using a two-step isopycnic
density gradient centrifugation procedure, as previously described
[19]. The weight-average molecular weight (Mw) and the weight-
average mean square radius (Rw) of mucins were determined by
size-exclusion chromatography and multi-angle laser light scat-
tering (SEC-MALLS), as described previously [17].
2.7. Statistical analysis
Data were analyzed using Prism (GraphPad Software Inc., CA,
USA). Normal distribution was assessed using the D'Agostino
and Pearson omnibus normality test. Results are quoted as mean
(SD) unless otherwise stated. Skewed data were log-transformed
prior to analysis. Paired t-test was used for comparison of change
in variables between paired time points. A p value of below 0.05
was considered as statistically significant.
3. Results
Data are available on 12 subjects (Table 1), median
age of 22 years. All patients were chronically infected
with P. aeruginosa. The majority of patients had significant lung
function impairment with a median baseline FEV1 of 37.8%
predicted.
3.1. Sputum rheology
Sputum samples from 12 patients underwent paired rheological
analysis before and after incubation at 37 °C for 60 min. Median
(range) baseline elastic modulus (G′) was 5.98 (2.74–16.6) Pa.
This fell significantly to 4.70 (1.12–6.36) Pa at 60 min (p = 0.01),
see Fig. 1.
In two larger volume samples with minimal G′ change on
incubation, DNase and DTT each caused larger falls in elastic
modulus than incubation with saline. Mucin depolymerization
by DTT appeared to have greatest effect on sputum elasticity:
mean change in G′ with saline was +19% (2.80 to 3.36 Pa),
mean change with DNase was −25% (2.62 to 1.77 Pa) and
mean change with DTT was −54% (2.16 to 0.80 Pa).Table 1
Demographic and clinical data.
Male/female 7/5
Age (years) 22 (18–43)
Best FEV1% predicted in previous 6 months 37.8 (28.6–90.8)
FEV1% predicted at start of exacerbation 30.8 (19.1–44.4) ⁎
BMI (kg/m2) 20.4 (17.1–22.3)
24 h sputum weight (g) 23 (12–129)
Data are presented as median (range). FEV1: forced expiratory volume in 1 s.
BMI: body mass index.
⁎ p = 0.0005 compared to baseline.3.2. MUC5AC concentration
PairedMUC5AC analyses were available on 9 patients: in two
cases there was insufficient sample and one case was excluded at
60 min because of processing error.
There was a significant fall in mean (SD) MUC5AC immuno-
reactivity after incubation, from 8.2 (6.0) to 5.2 (4.7) μg/ml (37%
reduction, p = 0.02), see Fig. 2. Mucins were not reduced prior to
electrophoresis, allowing visualization of different sized mucin
polymers (larger polymeric forms migrate less rapidly [17]). A
representative section of a Western blot is shown in Fig. 3A.
Although signal intensity decreased with time, there did not appear
to be a change in the configuration of mucin bands, consistent with
loss of immunoreactive epitope rather than depolymerization to
smaller forms.
3.3. MUC5B concentration
Paired MUC5B data are available from 8 patients (insufficient
sputum in one additional case). Mean (SD)MUC5B concentration
was greater than MUC5AC: 17.3 (8.9) μg/ml vs 8.5 (6.4) μg/mlFig. 2. Change in MUC5AC and MUC5B immuno-reactivity with incubation at
37 °C. Each pair of points represents sampling of the same sputum sample at
different time points. Horizontal bars represent group means.
Fig. 3. Representative section of Western blot of sputum samples showing (A) MUC5AC and (B) MUC5B immunoreactivity. Serial doubling dilutions of mucin
standards (dilution given below band) are given for each mucin. 3A: Lanes 6–10 represent a single sputum sample from one patient, sampled at multiple time points
during incubation at 37 °C (time given in minutes below the bands). Lanes 11–13 represent analyses of a sputum sample from a second patient during incubation at
37 °C, including 2 repeats from time 0 (sample times given in minutes). Different bands represent different molecular weight or polymeric forms of MUC5AC [17].
Bands appearing at the top of the gel represent the most highly polymerized forms, whose large molecular size retards progression through the gel. 3B: Vertical white
lines separate samples from different subjects. White arrows on the left indicate the different forms of MUC5B; 1 — low charge glycoform, 2 — high charge
glycoform, 3 — degraded mucin fragments [20].
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time 0 to 12.5 (7.7) μg/ml after incubation (28% reduction, p =
0.02) (see Fig. 2). To permit separation in gels, MUC5B samples
required reduction and appear in three bands, representing 2
different glycoforms (upper 2 bands) and a lower band of degraded
mucins [20] (see Fig. 3B). Unlike MUC5AC, there was not only a
reduction in signal intensity but also a change in configuration of
the bands (i.e. relative disappearance of less mobile bands).
3.4. Mucin molecular weight and size
Purified mucin fractions from the sputum of three patients
were analyzed for molecular size (Rw) and weight (Mw) by
SEC-MALLS before and after incubation. Changes in Mw and
Rw in individual samples broadly mirrored those seen in mucin
immuno-reactivity and rheology (see Fig. 4). Mucins in sample 1
appeared to be already substantially degraded at time 0, with
lower Mw and Rw than the other 2 samples. As with the mucin
concentrations in this sample, Mw and Rw both fell further after
incubation.
4. Discussion
Understanding the nature of airway secretions is vital to
understanding how CF progresses and, particularly in later stages
of the disease, to developing therapies to assist airway clearance.
This study provides additional findings that may help to explainsome of the earlier confounding observations on the importance
of mucins in CF sputum.
We have shown that both elasticity and mucin composition of
sputum can be expected to decline rapidly at body temperature. In
some subjects mucins within sputum appeared already substan-
tially degraded at the start of the experiment. These data are
consistent with previous findings that have shown a larger pro-
portion of smaller polymeric mucins in CF sputum compared to
the mucins in normal tracheobronchial secretions [13,21,22]. As
previously described, MUC5B appeared to be the predominant
mucin in CF sputum [12], though this may also reflect more rapid
degradation of MUC5AC [21]. Although it has been recognized
for some time that bacterial or host inflammatory cell proteases
in the sputum may degrade mucins [23], only recently has the
importance of such processes begun to be appreciated [24]. As
with previous studies [12,13], we also observed a wide range
of mucin levels in CF sputum and we have gone on to show
that this might represent differences in mucin degradation.
This has important implications for our understanding of earlier
observations. In particular, this may explain the finding that mucin
levels are lower in CF sputum than healthy controls [11]. The time
course of mucin degradation is rapid and highly variable, with an
average 30% reduction in mucin levels at 1 h. Since it is probable
that sputum has been residing within the proximal airways for
some time before expectoration [25], and since it is also unlikely
that mucins would depolymerize ex vivo but not in the airway, it
is reasonable to anticipate that mucins may already have been
Fig. 4. Change in total mucin concentration (black, dotted line) and elastic shear modulus (G′, gray) (top), and molecular weight (Mw, gray) and size (Rw, black,
dotted line) of purified mucins from sputum of three different CF patients. Each vertical column represents paired data from separate patients (numbered 1–3)
assessed before and after incubation at 37 °C for 60mins. Mw and Rw are shown at 90 min for sample 1 because of insufficient sample at 30 and 60 min for reliable
quantification, though the appearances were the same.
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airway sputum plugs may therefore have quite different MUC5AC
and MUC5B forms and apparent concentrations, and we cannot
infer these from expectorated sputum. Retention of distal secretions
may mean that they are subject to greater degrees of degradation.
Alternatively, the mucins in dense plugs may be protected to a
certain extent from the high levels of proteases found in the
proximal airways. This is consistent with the observation byBurgel
et al. that the lumen of small airways in CF lungs removed for
transplantation were characterized by mucus plugs and obstruction
[26].
We collected sputum samples from a single episode of expec-
toration, stored these on ice within 5 min and processed them
rapidly. This contrasts with sputum in earlier studies which was
collected over 30 min [11,14]. In both studies, patients were
chronically infected with P. aeruginosa, and a recent study has
described the in vitro effect of Pseudomonas-derived proteases on
mucin levels [24]. Although it is not possible to be certain whether
the low mucin levels in CF sputum represent differences in mucin
secretion or in their degradation by airway proteases, it is clear
from our data that this latter process has an important influence on
mucin immunoreactivity. Since patients in this study were under-
going an exacerbation, the role of this process in stable CF patients
and in healthy subjects also requires future clarification.
We observed that as MUC5B degraded with time, there was a
change in electrophoretic bands, indicating pututative differences
in degradation of the different glycoforms. For MUC5AC how-
ever the signal appeared to decrease more uniformly and banding
appearance was unchanged. This suggests a loss of epitopes for the
MAN5AC-I antiserum rather than the breakdown of MUC5ACinto smaller units, and the polymer may still be intact due to
disulphide bonding. For this reason we also applied SEC-MALLS
to selected large-volume mucin samples. This confirmed that the
time-dependent fall in immuno-reactive signal was mirrored by
changes in average molecular weight and size, consistent with
depolymerization of the mucin chains. If degradation affected the
two mucin forms differently however, with depolymerization
occurring predominantly within the MUC5B fraction, long chains
of MUC5AC might still contribute to the 3D gel structure of the
sputum.
In this study we have not included secretions from healthy
controls. These have been looked at previously and noted to show
temperature dependent degradation over 24 h similar in nature to
that observed here over 1 h, although in the earlier study other
timepoints were not reported [27]. Although the focus of the
current work was what was happening in CF, future studies to
investigate this phenomenon would benefit from comparison
with healthy controls and other disease groups.
Henke et al. concluded that the lower levels of mucins in CF,
and the high concentrations of DNA, indicated a more important
role for the latter in determining the physical characteristics of
sputum [11,28]. It is undoubtedly the case that DNA has an major
influence on CF rheology [29], and this is borne out by the clinical
impact of DNase and its role in airway clearance therapies. Our
data however also support a role for mucins. In two samples
that showed little or no change in rheology with incubation at
37 °C, greater impact on sputum elasticity was seen with DTT
(a compound known to solubilize mucins by reducing disulphide
bonds between mucin chains) than DNase. Although the numbers
are small, these preliminary observations agree with earlier in vitro
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Trials of both nebulized and oral N-acetylcysteine however have
been disappointing [31], and it is clear that a beneficial effect of
mucin solubilization is not universal. CF is by nature a highly
heterogeneous condition, with considerable differences in disease
expression both between and within patients. The suggestion that
inspissation of secretions is down to DNA alone has been based on
sputum from patients with significant lung disease, and all with
chronic infection with P. aeruginosa. The picture is further
complicated by the binding of proteases to DNA, such that
treatment with DNase may also permit greater degradation of
mucins [32]. Even if DNA was the predominant polymer in
freshly expectorated sputum, as emphasized here it would not
necessarily hold true for secretions retained in the lungs of these
patients. More importantly, it cannot be generalized to milder CF
patients where the infective load is less and mucin levels may be
higher [24]. Indeed, studies in early CF have detected physiolog-
ical evidence of airway obstruction even in the absence of overt
infection or inflammation [15]. Effective mucolytic therapies may
therefore be important in some patients or at earlier stages of the
disease.
In conclusion, we have provided important supporting evidence
that degradation of mucins occurs in the sputum of CF patients
with chronic infections. This occurs rapidly in both of the major
secreted mucin subtypes. Expectorated sputum may therefore be
quite different in elasticity and mucin composition from that
sequesteredmore distally in the lung. At present we lack good tools
to understand the nature of airway secretions and airway blockage
in the small airways in vivo. Future work should address the role of
mucins in the airways of patients free of P. aeruginosa. Important
information could be obtained from lower airway samples, either
obtained by hypertonic saline sputum induction or lower airway
brushings. Therapies aimed at improvingmucin solubilizationmay
yet have an important role in airway clearance.
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